Archimedes ?







The radiation oncologists are interested in Lazanda...it is a start.

At Friday's Advisory Committee for Zohydro the issue of the TIRF REMS came up and its impact on access. FDA said seems like there have been some issues and data will be available at some point in the future. Wonder what impact the REMS has had on scripts overall. Can't believe it's anything but bad.